UNSPSC 51314354: Chlorpheniramine/pseudoephedrine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE501. This VA Drug Class (RE501) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT.

UNSPSC 51314354 Chlorpheniramine/pseudoephedrine is a Commodity code that captures pharmaceutical procurement by state and local health agencies, though recent activity under the code shows limited direct alignment with the nominal scope. State and local governments use this code to solicit generic and branded pharmaceutical products, including over-the-counter remedies and allergy/cold medications, for distribution through public health facilities, county health departments, and cooperative purchasing vehicles serving multiple jurisdictions. Issuing bodies span state health and human services departments, county public health agencies, and multistate cooperative purchasing alliances—notably the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), which aggregates demand across participating state and local facilities, and the Texas Health and Human Services Commission, which coordinates pharmacy benefit procurement for state programs and health plans serving government employees and retirees.

Recent solicitations under the code show activity concentrated in Florida and Minnesota, with exploratory procurement underway in Texas. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually (response deadline July 26, 2026), reflecting public-health-emergency procurement rather than traditional allergy medications—a clear mismatch with the code's nominal scope. The Minnesota Department of Administration's MMCAP division issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and over-the-counter products, due March 26, 2026, with awards effective July 1, 2026 and distribution through three authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson) to participating state and local facilities in Minnesota and Oregon. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs, signaling exploratory procurement activity but no formal opportunity with response deadline or budget. The code shows limited recent volume and a significant scope misalignment in the available opportunities.